Last mentioned: Mar 24, 2026
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
Sentiment Review
Major analysts maintain existing price targets and ratings despite the earnings beat.
Analyst Upgrade
Wall Street Zen upgrades CDXS rating following financial results.
Q4 2025 Earnings
Codexis reports surprise profit and revenue beat.
TD Cowen Conference
CEO touts ECO Synthesis push and 2026 inflection targets.
52-Week High
EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
Analyst Upgrade
Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.
Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.